RESUMO
Objective To research the effect of Bifid Lriple Viable on validity for adjuvant treating ulcerative colitis,colon mucosa IgA and sera immunity indexes in patients with ulcerative colitis.Methods The patients with ulcerative colitis in our hospital from November 2004 to June 2006 were randomized into experiment group and control group.The patients in experiment group were treated with Bifid Lriple Viable and routine treatment,however the patients in control group received only routine treatment.The clinical symptom score,colon mucosa inflammation score,colon mucosa IgA expression,sera T lymphocyte subgroup,sera immunoglobulins and complement C3 and C4 were compared between two groups before treatment and two months after treatment.Results The clinical symptom score and colon mucosa inflammation score and colon mucosa IgA expression,sera T lymphocyte subgroup,sera immunoglobulins and complement C3 and C4 had no significant difference between two groups before treatment.Two months after treatment,the clinical symptom score and colon mucosa inflammation score descended significantly(P0.01),but the ascending value of ratio of CD4+ to CD8+ T lymphocyte was more in experiment group than control group(P